About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Speaker: Dr. Andrés Miguez González, Principal Investigator, Clinical Neuroimmunology Lab, Vall d'Hebron Research Institute (VHIR). Multiple Sclerosis Centre of Catalonia (Cemcat). CIBER of Neurodegenerative Diseases (CIBERNED)
Abstract: Multiple sclerosis (MS) is the leading cause of non-traumatic disability in young adults, affecting nearly 3 million people worldwide, with a mean age at diagnosis of 32 years. It is a chronic autoimmune disease of the central nervous system (CNS) characterized by inflammation, demyelination and neurodegeneration. Current MS therapies are highly effective in controlling peripheral immune-mediated inflammation, but have consistently failed to adequately target the CNS-intrinsic mechanisms underlying neurodegeneration and disease progression, which are thought to involve glial cells such as microglia, astrocytes and oligodendrocytes. Recent technological advances have revealed the functional heterogeneity of these glial cells in MS, highlighting their crucial roles in neuroinflammation, demyelination and remyelination.The lack of robust preclinical models based on human cells and tissues remains a major bottleneck for the translation of neuroprotective and remyelinating therapies in MS. To overcome this limitation and investigate the role of human glial cells in MS pathogenesis and progression, Dr. Andrés Miguez has developed New Approach Methodologies (NAMs) using a series of induced pluripotent stem cell (iPSC)-based humanized preclinical models: (i) In vivo human-mouse chimeras; (ii) Ex vivo human brain slice remyelination cultures; (iii) In vitro human myelination assays on engineered nanofibers.Alterations identified to date in these MS humanized models correlate with patient disability, highlighting glial-intrinsic dysfunction as a potential driver of clinical progression in MS. Ongoing single-cell spatial transcriptomics will provide deeper insights into differentially expressed genes in human oligodendrocytes and astrocytes across the disease course. Based on these data, small-molecule compounds able to modulate the expression of disease-associated genes will be selected and tested as potential neuroprotective and remyelinating therapies.
Follow it live: https://gencat.zoom.us/webinar/register/WN_owIjHFz7RNiuLevWM4XTEQ
